With Lek’s support, the 30th International Biennal of Graphic Arts enriches Slovenian artistic space
- The International Biennal of Graphic Arts, supported by Lek, a Sandoz company, is an example of a successful long-term integration of the economic and cultural spheres.
- On the occasion of the jubilee Biennal of Graphic Arts, Lek Gallery has organised an exhibition ‘A Tribute to Biennal’, exhibiting the works of eighteen young and older generation of local artists.
Tonight, the International Centre of Graphic Arts is opening its doors to the 30th Biennal of Graphic Arts, the long-term supporter of which is is Lek, a Sandoz company. This year’s edition will feature many exhibitions and artistic events, and Lek, a Sandoz company, will pay tribute to this jubilee Biennal with the exhibition Tribute to Biennal in the Lek Gallery. Activities with regard to the Biennal will be held from 24 November at various venues across Ljubljana.
Lek, a Sandoz company, supported the International Centre for Graphic Art in the staging of the Biennal of Graphic Arts in years 2003, 2005, 2007, 2009 and 2011 as well as in other exhibitions of local and foreign artists. »Once again this year’s Biennal of Graphic Arts is promising a top-level artistic experience, which Lek, a Sandoz company, was glad to support again this year. In this way we build on our core mission which is health care and a better quality of life but in addition we also support other areas in society. Among them culture features prominently, therefore we contribute to its existence and further development,« said Samo Roš, Head HR and member of the Board of Management of Lek, a Sandoz company, on the occasion of this year’s biennal.
The central exhibition within the 30th Biennal of Graphic Arts is Interruption, curated by Deborah Cullen, PhD, highlighting the evolution that the graphic field has undergone in the modern era. With this edition, the biennal of graphic arts goes back to the re-consideration of the nature of graphic processes and comments on how contemporary artists respond to contemporary communication processes and tools. Apart from the central exhibition, the Biennal of Graphic Arts also includes an accompanying exhibition on the complex history of one of the oldest Biennal globally The Biennal of Graphic Arts, With You Since 1955; traditional exhibitions of last year’s Biennal awardees, Regine José Galindo and Miklós Erdély, as well as a range of other accompanying exhibitions and events.
Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/eng/.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the rapidly growing generics industry. Sandoz offers a broad range of about 1, 100 high-quality, affordable products that are no longer protected by patents. With nearly 26,000 employees in approximately 140 countries, Sandoz holds the #1 position globally in biosimilars, injectables, ophthalmics and dermatology as well as a strong global #5 position in inhalables. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments, and hormone therapies. Sandoz develops, produces, and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US). In 2012, Sandoz posted sales of USD 8.7 billion. For more information, please visit www.sandoz.com.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32